- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Early symptomatic Alzheimer's disease
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Donanemab – July 2025
Donanemab; Solution concentrate for I.V. infusion 350 mg in 20 mL; Kisunla®
Last updated
9 July 2025